Factor Xa inhibitors versus warfarin in severely obese patients with venous thromboembolism or atrial fibrillation
HE Tierce, KA Lusk, AK Kitten, CM Long - American Journal of …, 2024 - ajpps.org
Objectives: Clinical data for the safety and efficacy of Factor Xa (FXa) inhibitors in severely
obese patients is limited. Additional information is needed to assess the risks and benefits of …
obese patients is limited. Additional information is needed to assess the risks and benefits of …